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 Background & Objective:  Diabetes vascular complications are the leading cause 
of death in the world. Therefore, we investigated the effect of pyridoxal phosphate 
(PLP) on the formation of atheromatous plaque and renal function in atherosclerotic 
rats.  
 Materials & Methods:  Forty male Wistar rats were randomly divided into four 
groups of normal, atherosclerotic, and two similar groups under PLP treatment. 
Atherosclerosis was induced in rats by an atherogenic diet and all groups were treated 
with 0.18% of PLP in drinking water daily for three months. Hematoxylin and eosin 
stain was applied to assess the histopathological changes in the aorta of subjects. 
Insulin resistance index, the activity of the glyoxalase (GLO) system, lipid profile, 
low-density lipoprotein (LDL) oxidation markers, advanced oxidation protein 
products, and inflammatory markers, such as high-sensitivity C-reactive protein (hs-
CRP) and TGF-β1 were examined in all rats. In addition, serum creatinine levels and 
urinary protein excretion of all animals were measured.  
Results:  Atheromatous lesions were not observed in the aorta of PLP-treated 
atherosclerotic rats. Furthermore, PLP seemed to improve insulin function, lipid 
profile, kidney function parameters, GLO system activity, and inflammation. We 
found that PLP treatment decreased the formation of LDL oxidation products both in 
vitro and in vivo (P<0.001).  
Conclusion:  According to our findings, PLP imposed a beneficial effect on 
vascular complications in atherosclerotic rats, which could be attributed to its 
antioxidant and anti-inflammatory properties. Moreover, PLP has positive impacts 
on insulin function, dyslipidemia, and GLO system activity. 
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Introduction
Atherosclerosis and nephropathy are common 
vascular complications of diabetes and are considered 
the leading cause of death in the world (1, 2). According 
to the literature, oxidative stress and inflammation 
induce insulin resistance and vice versa (3). 
Furthermore, insulin resistance, even in the absence of 
hyperglycemia, is an important factor in the 
pathogenesis of vascular complications (4, 5). Insulin 
resistance evokes inflammation and dyslipidemia along 
with interfering with insulin signaling in vascular cells, 
which occurs during atherosclerosis progress (5). 
Moreover, oxidative stress increases the level of 
transforming growth factor-β1 (TGF-β1) in the kidney 
as an important factor in nephropathy (6).  
Di-carbonyl compounds, such as methylglyoxal 
(MGO) have been known to lead to oxidative stress and 
inflammation contributing to a reduction in insulin 
secretion, insulin resistance, and vascular complications 
(7, 8). The diminished activity of the glyoxalase (GLO) 
system, as the main defense against MGO accumulation, 
in the presence and absence of hyperglycemia plays role 
in insulin dysfunction, atherosclerosis (9), and 
nephropathy (10). Therefore, the induction of GLO 
system activity has recently become a major therapeutic 
target in vascular complications (11) .  
Preventive medicine is suggested to be the best 
approach for managing vascular complications (12). We 
recently investigated the favorable effect of some natural 
products on diabetic vascular complications (13-15). 
Pyridoxal phosphate (PLP), the active form of vitamin 
B6, is an essential coenzyme in numerous metabolic 
reactions (16) and might play a crucial role in protecting 
cells against oxidative stress. Some evidence exhibited 
that the deficiency of vitamin B6 along with variations 
in its metabolism contribute to vascular disorders due to 
the induction of endothelial dysfunction, oxidative stress, 
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and inflammation (16, 17). Moreover, low circulating 
PLP is thought to be a possible indicator of inflammatory 
status and serum PLP is significantly correlated with the 
severity of coronary atherosclerosis (18). 
With this background in mind, we investigated the 
impact of PLP on the formation of atheromatous plaque 
and renal function in atherosclerotic rats. Furthermore, 
the inhibitory effect of PLP on the generation of LDL 
oxidation products under in vivo and in vitro conditions 
was studied. 
  
Materials and Methods 
Materials 
In this experimental study, all materials with analytical 
grade were purchased from Sigma and Merck Chemical 
Companies, Germany. 
In Vivo Studies 
Animals 
Nine-week-old male Wistar rats weighing 185±15 g 
were purchased from Pasteur Institute of Iran, Karaj. 
Animals were housed under controlled conditions with 
free access to food and water. After two weeks, they 
were divided into the two main groups of normal and 
atherosclerotic. Atherosclerosis was induced in rats 
with an atherogenic diet. Afterwards, each of the two 
main groups was divided into two subgroups of 10 rats. 
The normal groups were fed a standard chow diet, 
while the atherosclerotic groups were fed an 
atherogenic diet (a chow diet containing 1% 
cholesterol and 0.5% cholic acid). 
The subgroups were named as “N” for the normal 
group and “A” for the atherosclerotic group with no 
more treatments. The two similar subgroups under PLP 
treatment entailed N (PLP) and A (PLP), which received 
0.18% PLP daily in their drinking water for three 
months. The experiment protocol was approved with the 
code of IR.ARUMS.REC.1397-176 by Animal Ethics 
Committee in accordance with the guidelines for the care 
and use of laboratory animals prepared by Ardabil 
University of medical sciences.  
 At the end of the intervention, fasting blood samples 
were collected from the hearts of the rats and were then 
transferred to test tubes with and without EDTA. Serum 
samples were obtained by 10 min centrifugation of blood 
at 1500 g (4°C) and were stored at −70°C until further 
measurements. The aortas and kidneys of study rats were 
dissected and weighed immediately. 
Biochemical Parameters  
Fasting blood sugar (FBS), triglyceride (TG) (19), 
total cholesterol (TC), LDL, and high-density 
lipoprotein (HDL) were measured by enzymatic 
colorimetric methods. The LDL/HDL ratio was used to 
determine the atherogenic index. Serum insulin levels 
were determined using enzyme-linked immunosorbent 
assay (ELISA) using a rat insulin kit (Mercodia, 
Uppsala, Sweden). Moreover, a homeostasis model 
assessment of insulin resistance (HOMA-IR) was 
calculated. 
Methylglyoxal 
Serum MGO was measured utilizing reverse-phase 
high-performance liquid chromatography (HPLC) as 
explained previously (20).  
Oxidative and Inflammatory Markers 
Advanced oxidation protein products (AOPPs) as 
oxidative markers were assessed utilizing 
spectrophotometric detection according to the method of 
Witko-Sarsat et al. as described in our previous paper 
(20). Inflammatory markers, namely high-sensitivity C-
reactive protein (hs-CRP) and TGF-β1 were measured 
using CUSABIO ELISA kits (Wuhan, Hubei, China). 
LDL Oxidation Products  
Conjugated dienes (CDs) in LDL lipids, as early 
products of LDL oxidation, were analyzed 
spectrometrically at 234 nm. The fluorescence intensity of 
the end LDL oxidation product, named as oxidation 
fluorescent product (OFP), was recorded at the maximum 
emission of 430 nm upon excitation at 360 nm (20). 
Enzymatic Assay 
The activity of glyoxalase-1and 2 (Glo-I and Glo-II) 
in hemolysate was determined by measuring the rates of 
initial formation and hydrolysis of S-D-
lactoylglutathione and enzymes activity (20). 
Pathologic Study 
The entire aortas of all rats from all groups were 
collected and fixed in 10% buffered formalin. Next, 
sections were prepared from each segment and were 
stained with hematoxylin and eosin (H&E) stains for 
pathological examination.  
In Vitro Formation of LDL Oxidation Products 
LDL Extraction and Oxidation 
The LDL was extracted from serum specimens and 
was incubated with CuSO4 in the absence and presence 
of 0.18% PLP. The procedure of extraction and 
incubation was similar to what was explained previously 
(21). Briefly, LDL was isolated from the sera of normal 
rats with sodium heparin and was incubated in the 
presence and absence of CuSO4 (10 mmol/L) and PLP 
(15 mmol/L).  
Oxidized LDL Products 
The resistance of LDL against oxidative modification 
with CuSO4, with and without PLP, was determined 
photometrically at 234 nm (22). In addition, the FOP of 
LDL was measured by the method explained in the 
“LDL Oxidation Products” section. 
Statistical Analysis 
Descriptive analysis of all data was expressed as 
mean±standard deviation (SD). Multivariate analysis of 
variance (MANOVA) test with Tukey posthoc test was 
used to compare the different variables assessed in all 
four groups utilizing the SPSS 16 (SPSS Inc., Chicago, 
IL., USA). Statistical significance was considered as  
P-value< 0.05. 
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Results  
In Vivo Experiments 
The impacts of PLP administration on the formation 
of aortic lesions in normal and atherosclerotic rats are 
shown in Figures 1a-1b. Neointima (Figure 1b) and 
aorta plaque were found only in the atherosclerotic rats. 
However, the vitamin interfered with the generation of 
any aortic lesions. Furthermore, the histological 
observations in the aorta of the treated atherosclerotic 
rats were similar to those of the untreated and treated 
normal groups (Figure 1a).  
 
   
Figure 1. Effect of pyridoxal phosphate on atheromatous plaque formation in normal (N) and atherosclerotic (A) rats 
(stained by H&E & original magnification ×200). (a) Normal aorta in N, N (PLP) and A (PLP) groups. (b) Formation of 
neointima in A group. (c) Atherosclerosis plaque formation in A group 
 
Table 1 represents the results of FBS, insulin, HOMA-
IR, lipid profile, and kidney dysfunction tests in all 
groups. Insulin, HOMA index (as a marker of insulin 
resistance), TG, TC, LDL, and the atherogenic index 
increased significantly due to atherosclerosis 
induction. Our findings demonstrated that PLP 
compensated for these changes and decreased the 
levels of TC and TG in the treated, normal, and 
atherosclerotic groups. Furthermore, Cr, PU, and 
kidney weight index (as kidney dysfunction tests), as 
well as TGF-β1 (Table 2) were lower in the treated 
atherosclerotic group than in the untreated group 
(P<0.001).  
Results of comparing oxidative markers, inflammatory 
factors, the activity of the GLO system, and MGO 
levels between all groups are summarized in Table 2. 
Reductions in the AOPP, LDL oxidation products, and 
hs-CRP of the atherosclerotic rats reveals that the 
treatment exerted antioxidant and anti-inflammatory 
influences (P<0.001). Furthermore, PLP induced Glo-
I and Glo-II activity and diminished MGO levels in the 
mentioned groups (P<0.001).  
 
Table 1. The effect of pyridoxal phosphate (PLP) on FBS, insulin, HOMA-IR, lipid profile, and kidney function tests in 
normal (N) and atherosclerotic (A) rats. 
Parameter 
Groups 
N N (PLP) A A (PLP) 
Fasting blood sugar (mmol/L) 4.49 ± 0.26 3.97 bb b ± 0.29 4.89 ± 0.47* 4.66 ± 0.4 *, # 
Insulin (µU/mL) 17.91 ± 1.36 18.53± 0.67 26.84 ± 0.60 * 21.89 ± 0.55 *, # 
HOMA-IR  3.57 ± 0.15 3.26 ± 0.17 5.83 ± 0.18 * 4.53 ± 0.16 *, # 
Triglyceride (mmol/L) 0.93 ± 0.03 0.78 ± 0.02 *,  2.83 ± 0.08 * 1.02 ± 0.03 *, # 
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Parameter 
Groups 
N N (PLP) A A (PLP) 
Total cholesterol (mmol/L) 2.22 ± 0.07 1.99 ± 0.09 *, # 6.42 ± 0.16 * 4.44 ± 0.13 *, # 
HDL (mmol/L) 1.30 ± 0.05 1.25 ± 0.05 0.43 ± 0.01 * 0.78 ± 0.02 *, # 
LDL (mmol/L) 0.43 ± 0.02 0.33 ± 0.01 4.68 ± 0.12 * 3.20 ± 0.06 *, # 
HDL/LDL 0.33 ± 0.01 0.27 ± 0.01 *, # 11.00 ± 0.21 *  4.15 ± 0.11 *, # 
Creatinine (µmol/L) 61.50± 4.24 57.33 ± 1.86 96.50± 5.74 * 71.00 ± 2.60 *, # 
Proteinuria (mg/24 h) 13.00 ± 0.57 10.87 ± 0.40 347.50 ± 17.50 * 170.00 ± 8.11 *, # 
Kidney weight index (g/100g body weight) 0.86 ± 0.06 0.87 ± 0.05 1.23 ± 0.09 * 0.98 ± 0.08 *, # 
* Indicates significance of data comparing group N with other groups (P<0.001) 
# Indicates significance of data comparing group A with other groups (P<0.001) 
 
Table 2. Effect of pyridoxal phosphate (PLP) on glyoxalase activity and methylglyoxal level as well as oxidative stress and 
inflammatory markers of the normal (N) and atherosclerotic (A) Rats. 
Parameter 
Groups 
N N (PLP) A A (PLP) 
Methylglyoxal (µmol/L) 15.50 ± 1.60 13.12 ± 0.63 93.00 ± 5.10 * 48.60 ± 2.30 *, # 
Glyoxalase-I (U/mL) 32.64 ± 1.89.90 41.03 ± 2.33 *, # 19.91 ± 0.95 * 30.75 ± 2.01 *, # 
Glyoxalase-II (U/mL) 33.42 ± 1.96 42.65 ± 2.76 *, # 21.53 ± 1.20 * 28.63 ± 1.97 *, # 
Early oxidation products of LDL  
(µmol/L) 
13.81± 0.89 12.95 ± 0.75 *, # 108.33 ± 5.45 * 67.61 ± 5.67 *, # 
End oxidation products of LDL  
(µmol/L) 
248.73 ± 12.33 227.65 ± 10.05 *,# 514.83 ± 27.30 * 432.37 ± 22.97
  *, # 
Advanced oxidation protein products  
(µmol/L) 
28.80 ± 1.02 18.82 ± 0.85 *, # 89.14 ± 3.23 *  61.83 ± 2.84  *, # 
hs CRP (ng/mL) 235.02± 10.23 187.15 ± 7.55 *, # 596.77± 25.21 * 400.23 ± 17.81 *, # 
TGF-β1 (pg/mL) 26.32± 1.43 23.89 ± 1.09  87.23± 6.20* 56.46 ± 3.62 *, # 
* Indicates significance of data comparing group N with other groups (P<0.001) 
# Indicates significance of data comparing group A with other groups (P<0.001) 
 
In Vitro Study 
The levels of early and end LDL oxidation products  
(Table 3) decreased following the treatment. 
 
 
Table 3. The effect of pyridoxal phosphate (PLP) on the formation of LDL oxidation products in the test tube experiment 
Tube Content Early oxidation products (µmol/L) End Oxidation products (AU) 
LDL 16.94±0.57 15.17±0.44 
LDL+ CuSO4 135.56±4.55 500.01±10.84 
LDL+ CuSO4 + PLP 50.83±1.22 110.01±2.36 
 
Discussion 
According to the results of the current study, PLP 
reduced the levels of the markers of oxidative stress, 
carbonyl stress, and inflammation in atherosclerotic 
rats. It could be concluded that PLP prevented the 
formation of atheromatous lesions and improved 
kidney function in these animals. Furthermore, PLP 
had a corrective effect on insulin resistance, 
dyslipidemia, and the activity of the GLO system. 
Moreover, the inhibitory effect of the treatment on in 
vitro LDL oxidation confirms the obtained results. 
The PLP was shown to impose positive effects on 
microvascular and macrovascular diseases. According 
to the pathologic investigation (Figures 1) and the 
Sina Mahdavifard & Manochehr Nakhjavani   25 
      Volume 29, Januery & February 2021       Journal of Advances in Medical and Biomedical Research 
results of kidney dysfunction tests (Table 1), this 
vitamin suppressed the development of atheromatous 
lesions and ameliorated kidney dysfunction by 
reducing serum TGF-β1, creatinine, proteinuria, and 
kidney weight index in the atherosclerotic rats.  
The studied vitamin diminished insulin resistance in 
the atherosclerotic rats (Table 1) owing to the 
beneficial impact on insulin function. Oxidative stress 
and inflammation might provoke insulin resistance and 
vascular complications. Di-carbonyl compounds, such 
as MGO, are sources of oxidative stress and 
inflammatory markers that reduce insulin secretion, 
insulin resistance, and vascular complications (7, 8). 
The activity of the GLO system, which is the most 
important pathway for decreasing methylglyoxal, is 
disturbed in atherosclerotic rats (Table 2). According 
to the literature, the effect of PLP on GLO system 
activity in atherosclerotic patients was not studied. 
Previously, the protective effect of PLP against STZ-
induced beta-cell dysfunction was reported (23).  
The AOPPs are biomarkers of oxidative stress and 
inflammatory mediators and hs-CRP is a biomarker of 
systemic inflammation. These factors may enhance 
insulin resistance (24), atherosclerosis (25), and 
nephropathy (26). Based on Table 2, the treatment 
decreased the levels of AOPP and hs-CRP in normal 
and atherosclerotic rats (P<0.001). The elevation of 
antioxidant enzyme activity in surgical patients under 
PLP treatment (27) confirms our results regarding the 
antioxidant effect of PLP.  
Dyslipidemia is a prevalent aspect of atherosclerosis 
and nephropathy (28). Treatment with PLP corrected 
the lipid profiles of normal and atherosclerotic rats 
(Table 1). Moreover, the vitamin decreased the levels 
of TC, LDL, and atherogenic index in diabetic rats, 
whereas only TG and TC were reduced in the normal 
group (P<0.001). As far as we know, the present 
investigation indicates the beneficial effect of PLP on 
the lipid profiles of atherosclerotic rats for the first 
time.  
Hyperlipidemia and oxidative stress exacerbate LDL 
oxidation. Furthermore, hypercholesterolemia 
augments the changes in LDL contributing to the 
initiation and progression of atherosclerosis. Our 
results indicated that the treatment reduced the early 
and end oxidation products of LDL in normal and 
atherosclerotic rats in vitro (Tables 2 and 3). The 
diminishing effect of PLP on LDL oxidation in 
atherosclerotic rats had not been reported previously. 
Based on our previous studies, the treatments that 
inhibit the generation of the end oxidation products of 
LDL can prevent the development of all types of 
atheromatous lesions (20, 21).  
 
Conclusion 
Our findings revealed that PLP prevented the 
formation of atheromatous lesions and ameliorated 
renal dysfunction in atherosclerotic rats due to its 
antioxidant and anti-inflammatory properties. 
Furthermore, PLP had beneficial effects on insulin 
function, dyslipidemia, and GLO system activity. It 
could be concluded that PLP is useful in the treatment 
of diabetes. 
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